홈 › 비소세포폐암 › 펜실베이니아

펜실베이니아의 비소세포폐암 임상 시험

비소세포폐암 관련 연구 103개가 펜실베이니아 내 여러 지역에서 참여자를 모집하고 있습니다.

펜실베이니아의 도시

공식 연구 텍스트(영어)

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Alliance Cancer Specialists, Sellersville

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT06765109

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Lancaster General Hospital, Lancaster
Local Institution - 0028, Pittsburgh
WellSpan Oncology Research, York

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT07361510

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Lehigh Valley Hospital-Cedar Crest, Allentown
UPMC Altoona, Altoona
UPMC-Heritage Valley Health System Beaver, Beaver
외 53개

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT04267848

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Spoknwrd Clinical Trials /ID# 273776, Easton

피험자 모집 중1/2상

18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT06772623

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Research Site, Pittsburgh

피험자 모집 중1상

18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT05877599

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Penn State Milton S. Hershey Medical Center, Hershey

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT06881784

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Lehigh Valley Hospital-Cedar Crest, Allentown
Lehigh Valley Hospital - Muhlenberg, Bethlehem
Bryn Mawr Hospital, Bryn Mawr
외 14개

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT06498635

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0111), Lancaster

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07190248

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

St. Lukes Hospital and Health Network ( Site 0186), Bethlehem

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06623422

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Alliance Cancer Specialists, PC, Bensalem
Consultants in Medical Oncology and Hematology, P.C., Broomall
Alliance Cancer Specialists, PC, Doylestown
외 5개

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07144280

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Perelman Center for Advanced Medicine ( Site 3205), Philadelphia

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07513376

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Research Site, Philadelphia
Research Site, Pittsburgh

피험자 모집 중1상

18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06218914

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Research Site, Fountain Hill
Research Site, Kittanning
Research Site, Philadelphia

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06868277

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Alliance Cancer Specialists - Media, Media
Guthrie Medical Group, Sayre

피험자 모집 중3상

18세 ~ 100세 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT05920356

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Thomas Jefferson University Hospital, Philadelphia
Jefferson Health Northeast, Philadelphia
McGlinn Cancer Institute Reading Hospital, West Reading

피험자 모집 중2상

18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06667076

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Penn State Milton S. Hershey Medical Center-Penn State Cancer Institute ( Site 0059), Hershey
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0068), Lancaster

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06312137

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

University of Pennsylvania, Philadelphia

피험자 모집 중2상

18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06667908

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Lehigh Valley Hospital-Cedar Crest, Allentown
Lehigh Valley Hospital - Muhlenberg, Bethlehem
Bryn Mawr Hospital, Bryn Mawr
외 5개

피험자 모집 중2상

18세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT03191149

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
Jefferson Hospital Northeast, Philadelphia
AHN Allegheny General Hospital, Pittsburgh

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT06890598

Pan-tumor MRD Study

Lancaster General Hospital (UPenn), Lancaster
Guthrie Foundation, Sayre
Cancer Care Associates of York (CCAY), York

피험자 모집 중관찰 연구

18세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT06605404

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site, Pittsburgh

피험자 모집 중2상

18세 ~ 95세 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT05061550

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
Local Institution - 0504, Philadelphia

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT06561386

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Allegheny Health Network, Pittsburgh

피험자 모집 중1/2상

18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT06128551

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Hospital of the University of Pennsylvania, Philadelphia
West Penn Allegheny Health, Pittsburgh

피험자 모집 중2/3상

18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07100080

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Local Institution - 0688, Easton
WellSpan Oncology Research, York

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT06875310

An External Control Arm Study in Non-Small Cell Lung Cancer

Main Line Health, Wynnewood

피험자 모집 중관찰 연구

18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07174388

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

Lankenau Medical Center, Paoli

피험자 모집 중관찰 연구

18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07028489

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Guthrie Robert Packer Hospital /ID# 270316, Sayre
Cancer Care Associates Of York /ID# 270971, York

피험자 모집 중2상

18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT06568939

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Hershey
Research Site, York

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 18. 업데이트됨 · NCT06692738

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Site, Philadelphia
Clinical Study Site, Pittsburgh

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 18. 업데이트됨 · NCT06767514

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

UPMC, Pittsburgh

피험자 모집 중1상

18세 이상 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT07020117

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Veterans Affairs Pittsburgh Healthcare System - University Drive Campus, Pittsburgh

피험자 모집 중2/3상

18세 이상 · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT04613596

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Abramson Cancer Center of the University of Pennsylvania, Philadelphia
University of Pittsburgh Medical Center, Pittsburgh
WellSpan York Cancer Center, York

피험자 모집 중1/2상

12세 이상 · 모든 성별 · 2026. 9. 15. 업데이트됨 · NCT04585750

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

University of Pennsylvania, Philadelphia
WellSpan Medical Oncology & Hematology at York Cancer Center, York

피험자 모집 중관찰 연구

18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT05059444

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Allegheny Singer, Pittsburgh

피험자 모집 중1/2상

18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT06303505

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

St. Luke's University Health Network, Bethlehem
Allegheny Cancer Center, Pittsburgh
Reading Hospital - McGlinn Cancer Institute, West Reading

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT06793215

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

USO - Alliance Cancer Specialists, PC, Horsham
Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
UPMC Hillman Cancer Center, Pittsburgh

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT06119581

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0134), Lancaster

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT06345729

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

UPMC Hillman Cancer Center, Pittsburgh

피험자 모집 중1/2상

18세 이상 · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT07012031

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Site, Hershey
Research Site, Lancaster

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT07291037

ClinicalTrials.gov 출처, 2026. 10. 1. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.